October 18, 2019 10:54 AM EDT
News Briefing

An­sun Bio­phar­ma clos­es $80M Se­ries B; Red­Hill Bio­phar­ma ties up with Cos­mo Phar­ma­ceu­ti­cals

Kathy Wong

Editor

→ San Diego-based An­sun Bio­phar­ma re­cent­ly closed an $80 mil­lion Se­ries B fund­ing round, led by Chi­na In­vestors, ac­cord­ing to Chin­aBio To­day. The funds …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times